Inositol
Vitamin-Like CompoundAlso known as: Myo-Inositol · D-chiro-inositol · Vitamin B8
Inositol is a naturally occurring sugar alcohol that functions as a critical second messenger in cellular signaling, particularly through the IP3 pathway and insulin signal transduction. It is found in a range of foods and is produced endogenously. The most studied form, myo-inositol, has its strongest evidence base in polycystic ovary syndrome (PCOS), where it appears to improve insulin sensitivity and hormonal regulation. High-dose myo-inositol (12-18g/day) has been studied for anxiety and panic disorder with preliminary positive findings. Lower-dose use for sleep (approximately 900mg) is discussed in wellness contexts but has limited direct trial evidence at that specific dose.
Evidence Summary
All 3 studiesInositol is a naturally occurring sugar alcohol that functions as a second messenger in cellular signaling — specifically through the phosphatidylinositol (PI) pathway and inositol trisphosphate (IP3) signaling. It plays roles in insulin signal transduction, serotonin and dopamine receptor function, and the regulation of FSH and LH in the hypothalamic-pituitary-ovarian axis. Myo-inositol is the most abundant naturally occurring stereoisomer, found in fruits, beans, and whole grains. D-chiro-inositol is produced from myo-inositol via an insulin-regulated epimerase reaction. The strongest evidence for inositol supplementation is in polycystic ovary syndrome (PCOS). Multiple randomized controlled trials and at least one systematic review (Unfer et al., 2017) support myo-inositol (typically 4g/day) for improving insulin sensitivity (HOMA-IR), reducing elevated androgens, improving LH/FSH ratios, and restoring menstrual regularity in women with PCOS. The 40:1 myo-inositol to d-chiro-inositol ratio has been proposed as physiologically relevant based on the ratio found in ovarian follicular fluid. This evidence base is considered moderate in strength — more robust than most supplement categories, though still limited by trial size and heterogeneity. Evidence for anxiety and panic disorder is based on a smaller literature and should be interpreted cautiously. A double-blind crossover RCT (Palatnik et al.) found that 18g/day of inositol reduced panic attack frequency to a comparable degree as fluvoxamine over one month, with fewer side effects. OCD evidence is present but less consistent. These findings are intriguing but have not been replicated in large trials. The doses involved (12-18g/day) are substantially higher than doses discussed for other uses (900mg for sleep), and the GI side effect profile at these doses is notable. The lower-dose use of inositol (900mg before sleep) has been popularized in wellness contexts, including by researchers like Andrew Huberman. The evidence base for this specific application is limited, though inositol's role in serotonin receptor modulation provides a plausible mechanistic rationale. This should be considered a low-evidence application at present. Safety profile across all uses is generally favorable at doses under 4g/day. At higher doses (12-18g/day), GI side effects including nausea, flatulence, and loose stools are common and dose-dependent. A significant caution exists for individuals with bipolar disorder: theoretical and case-report level evidence suggests high-dose inositol may precipitate manic episodes, possibly through its role in second messenger signaling. This is a meaningful clinical concern that warrants avoidance of high-dose inositol in bipolar patients without psychiatric guidance. Use during pregnancy should be discussed with a qualified healthcare provider.
Read full evidence summary →Top studies
Effects of Myo-inositol in Women with PCOS: A Systematic Review of Randomized Controlled Trials
Myo-inositol supplementation significantly improved hormonal profiles, insulin sensitivity, and menstrual regularity in women with PCOS. The 40:1 myo-inositol to d-chiro-inositol ratio was identified as physiologically relevant.
May improve hormonal balance, insulin sensitivity, and menstrual regularity in women with PCOS
Generally well-tolerated; mild GI upset (nausea, diarrhea) at doses above 4g/day
Heterogeneity across included trials; variable dosing protocols; most trials relatively short-duration (3-6 months)
Myo-Inositol and D-Chiro-Inositol in Improving Insulin Resistance in Women with Metabolic Syndrome
Myo-inositol supplementation (4g/day) was associated with improvements in fasting glucose, HOMA-IR, and triglycerides compared to placebo in women with metabolic syndrome over 6 months.
May support improvements in metabolic markers in women with metabolic syndrome
No serious adverse events reported; mild GI symptoms in a minority of participants
Small sample size; women only; metabolic syndrome is a heterogeneous condition; results may not generalize broadly
Expert Mentions
All 3 mentions"Inositol is interesting because there's a dose-dependent effect. There's data showing that 12 to 18 grams — which is a very large amount — can reduce anxiety and panic attacks, and there's been a direct comparison to fluvoxamine. But there's also some data around 900 milligrams before sleep that people find helpful for sleep. Very different doses, very different contexts."
Myo-inositol taken at high doses (12-18g/day) has evidence for reducing anxiety and panic, while a lower dose around 900mg taken before sleep may support sleep quality — the effects are meaningfully dose-dependent.
The 12-18g/day for anxiety and panic is supported by a small double-blind crossover RCT (Palatnik et al.), though the evidence base is limited in size. The 900mg for sleep is a much lower-evidence claim — some users report benefit, but clinical trials specifically at this dose for sleep are limited. Huberman's characterization of dose-dependency is accurate and reflects the available literature honestly.
"There's actually been clinical research on inositol for OCD and panic disorder going back to the 1990s. The doses used were very high — around 18 grams a day — and in some studies it performed comparably to SSRIs for panic. I want to be careful here though: these were small studies, and this is not a replacement for evidence-based psychiatric treatment."
Inositol has been studied for OCD and panic disorder at doses of 12-18g/day with modest evidence. It may be a reasonable consideration for patients who cannot tolerate SSRIs, though the evidence base is small and replication is needed.
Marks accurately characterizes the inositol-OCD/panic literature. A double-blind crossover RCT by Palatnik et al. did show panic attack reduction at 18g/day versus fluvoxamine. However, the OCD evidence is weaker and less consistent, and the overall evidence base is small (few trials, small n). Her caution about not replacing standard psychiatric treatment is clinically appropriate.
Key findings
- ·Strongest evidence is in PCOS: myo-inositol (4g/day) has RCT support for improving insulin sensitivity, hormonal profiles, and menstrual regularity.
- ·The 40:1 myo-inositol to d-chiro-inositol ratio reflects ovarian physiology and may be the most effective formulation for PCOS.
- ·High-dose inositol (18g/day) showed comparable efficacy to fluvoxamine for panic disorder in a small crossover RCT, though this evidence has not been replicated at scale.
Evidence gaps
- ·Large-scale, well-powered RCTs for anxiety and panic disorder are lacking; existing trials have small sample sizes.
- ·Long-term safety data (beyond 6 months) is limited across all indications.
- ·Head-to-head comparison of inositol forms (myo alone vs. 40:1 combination) across metabolic outcomes needs more study.